China Isotope & Radiation Corp. released its earnings results on Aug 28, 2025. The company reported HK$0.578 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.578.

Is China Isotope & Radiation Corp. overvalued?

According to Wall Street analysts China Isotope & Radiation Corp.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does China Isotope & Radiation Corp. pay dividends?

China Isotope & Radiation Corp. pays a Monthly dividend of HK$0.088 which represents an annual dividend yield of 2.69%. See more information on China Isotope & Radiation Corp. dividends here

What is China Isotope & Radiation Corp.’s EPS estimate?

China Isotope & Radiation Corp.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does China Isotope & Radiation Corp. have?

China Isotope & Radiation Corp. has 79,968,800 shares outstanding.

What happened to China Isotope & Radiation Corp.’s price movement after its last earnings report?

China Isotope & Radiation Corp. reported an EPS of HK$0.578 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.241%.

Which hedge fund is a major shareholder of China Isotope & Radiation Corp.?

Currently, no hedge funds are holding shares in HK:1763

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

China Isotope & Radiation Corp. Stock Smart Score

Outperform

Technicals

Fundamentals

Return on Equity

8.59%

Trailing 12-Months

Asset Growth

16.12%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

China Isotope & Radiation Corp.

China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Independent Clinical Medical and Laboratory Services, and Other Business. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals; UBT kits and analyzers; and in vitro immunoassay diagnostic reagents and kits. The Radioactive Source Products segment provides medical and industrial radioactive sources products and related technical services. The Irradiation segment offers irradiation services to manufacturers of medical devices, food, traditional Chinese medicine, and cosmetics for sterilization; and EPC services for the design, manufacturing, and installation of gamma ray irradiation facilities. The Radiation Therapy Equipment and Related Services segment sells radiation therapy equipment; and provides related maintenance services. The Independent Clinical Medical and Laboratory Services, and Other Business segment provides independent clinical laboratory services with respect to hepatitis, endocrine, bone metabolism, cardiovascular disease, diabetes, and other diseases to hospitals and other medical institutions. The company was founded in 1983 and is headquartered in Beijing, China. China Isotope & Radiation Corporation is a subsidiary of China National Nuclear Corporation.